A detailed history of Qube Research & Technologies LTD transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 188,933 shares of NTLA stock, worth $2.61 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
188,933
Holding current value
$2.61 Million
% of portfolio
0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.72 - $27.36 $3.73 Million - $5.17 Million
188,933 New
188,933 $3.88 Million
Q1 2024

May 14, 2024

SELL
$23.82 - $32.8 $4.67 Million - $6.43 Million
-196,103 Reduced 81.48%
44,588 $1.23 Million
Q4 2023

Feb 13, 2024

BUY
$23.16 - $32.34 $4.53 Million - $6.32 Million
195,432 Added 431.81%
240,691 $7.34 Million
Q3 2023

Nov 13, 2023

SELL
$31.62 - $45.78 $774,089 - $1.12 Million
-24,481 Reduced 35.1%
45,259 $1.43 Million
Q2 2023

Aug 14, 2023

BUY
$34.58 - $46.03 $1.62 Million - $2.15 Million
46,774 Added 203.67%
69,740 $2.84 Million
Q1 2023

May 15, 2023

SELL
$33.3 - $44.82 $62,237 - $83,768
-1,869 Reduced 7.53%
22,966 $855,000
Q4 2022

Feb 14, 2023

BUY
$33.21 - $62.69 $824,770 - $1.56 Million
24,835 New
24,835 $866,000
Q2 2022

Aug 15, 2022

SELL
$38.49 - $76.21 $637,856 - $1.26 Million
-16,572 Closed
0 $0
Q1 2022

May 09, 2022

BUY
$58.27 - $118.99 $965,650 - $1.97 Million
16,572 New
16,572 $1.2 Million
Q4 2021

Feb 01, 2022

SELL
$100.76 - $138.36 $166,455 - $228,570
-1,652 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$132.37 - $176.78 $2.24 Million - $2.99 Million
-16,932 Reduced 91.11%
1,652 $222,000
Q2 2021

Aug 13, 2021

BUY
$60.88 - $161.91 $1.13 Million - $3.01 Million
18,584 New
18,584 $3.01 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.05B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.